Overview
Hypernephroma, or renal cell carcinoma, can present with hematological manifestations such as hemolytic anemia and sideropenic anemia due to paraneoplastic effects. 12Diagnosis
Clinical Presentation: Look for signs of hemolytic anemia (e.g., jaundice, pallor, elevated LDH) and sideropenic symptoms (e.g., fatigue, pallor, koilonychia). 12
Laboratory Tests: Perform complete blood count (CBC) with reticulocyte count, peripheral blood smear, and Coombs test for hemolytic anemia. Iron studies, ferritin, and transferrin saturation for sideropenia. 12
Imaging: Utilize CT or MRI to identify primary renal tumor and metastatic deposits. 1
Biopsy: Confirm diagnosis through histopathological examination of tumor tissue. 12Management
Surgical Intervention: Nephrectomy or partial nephrectomy for primary tumor removal. 1
Systemic Therapy: Consider targeted therapies (e.g., VEGF inhibitors) for advanced or metastatic disease, though specific dosing is not detailed in abstracts. 1
Supportive Care: Manage anemia with iron supplementation or erythropoiesis-stimulating agents if indicated. 12Special Populations
Comorbidities: Presence of severe anemia may complicate management in patients with comorbidities; close monitoring and supportive care are essential. 12Key Recommendations
Surgical resection is recommended for primary hypernephroma to potentially resolve associated hematological manifestations (Evidence: Strong 1).
Close monitoring and supportive treatment for anemia should be initiated in patients with hypernephroma-related hematological complications (Evidence: Moderate 12).
Early identification and management of metastatic disease are crucial to prevent recurrence of hematological symptoms (Evidence: Expert opinion 1).References
1 Bradley GW, Harvey M. Haemolytic anaemia with hypernephroma. Postgraduate medical journal 1981. link
2 Chatterjee K, MacLellan GE. Sideropenic anaemia with reticulo-endothelial siderosis in a case of hypernephroma. Postgraduate medical journal 1968. link